AccurKardia is launching a pivotal pilot for its AK+ GuardTM technology, which leverages AI to detect hyperkalemia through Lead I ECG, signaling a significant advancement in ECG-based diagnostics. This initiative not only aims to enhance patient safety but also positions AccurKardia at the forefront of AI integration in healthcare, addressing a critical and prevalent medical condition.
NEW YORK–(BUSINESS WIRE)– #AIinHealthcare–AccurKardia, an innovator in ECG-based diagnostics technology, has announced the initiation of a multicenter clinical pilot of AK+ GuardTM, an FDA Breakthrough Device Designated AI-powered technology that enables the detection of hyperkalemia using Lead I ECG. The three-arm prospective pilot study will evaluate more than 150 patients across inpatient, outpatient and home settings in the U.S. Hyperkalemia, or an excess of serum potassium in the blood, is a common condi
Source: Original Press Release
